Sunitinib: all 340 studies that test it
Page 3 of 4. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.
- Study to Assess Various Sunitinib Schedules in Renal Cell CarcinomaStatus unknownNCT02689167Phase 2
- A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian PopulationTerminatedNCT02626754Phase 2
- A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic CarcinomaCompletedNCT02623127Phase 2
- Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell CarcinomaCompletedNCT02555748Phase 4
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
- Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid TumorsCompletedNCT02450123Not applicable
- A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced MelanomaWithdrawnNCT02400385Phase 2
- A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.Status unknownNCT02398552Phase 2
- Multiple Treatments for Ebola Virus Disease (EVD)Status unknownNCT02380625Phase 1/2
- HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)Status unknownNCT02239952Not applicable
- CRIZENT: Crizotinib and Sunitinib in Metastatic Breast CancerTerminatedNCT02074878Phase 1
- Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell CarcinomaTerminatedNCT02071641Phase 2
- Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal MelanomaActive, not recruitingNCT02068586Phase 2
- Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.CompletedNCT02058901Phase 1
- Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional RegimenStatus unknownNCT01850147Phase 2
- Sunitinib® in Patients With Recurrent Ovarian Clear Cell CarcinomaCompletedNCT01824615Phase 2
- Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid TumorsStatus unknownNCT01803503Phase 2
- Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal CancerTerminatedNCT01784978Phase 2
- A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid TumorsStatus unknownNCT01731925Phase 2
- A Study of Sunitinib in Patients With Advanced CholangiocarcinomaCompletedNCT01718327Phase 2
- Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.CompletedNCT01636908Not applicable
- A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal MelanomaCompletedNCT01551459Phase 2
- To Assess the Interaction Between Sunitinib and Ketoconazole to Reduce the Dose and Cost of SunitinibCompletedNCT01548170Phase 1
- Study of Efficacy and Safety of Sunitinib Given on an Individualized ScheduleCompletedNCT01499121Phase 2
- Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue SarcomaCompletedNCT01498835Phase 1
- A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.WithdrawnNCT01441388Phase 1
- Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer PatientsCompletedNCT01402089Phase 4
- A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare TumoursActive, not recruitingNCT01396408Phase 2
- First International Randomized Study in Malignant Progressive Pheochromocytoma and ParagangliomaCompletedNCT01371201Phase 2
- Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)CompletedNCT01309633Phase 2
- Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant RadiotherapyCompletedNCT01308034Phase 1
- Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid TumorsCompletedNCT01286896Phase 1
- Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid MalignanciesCompletedNCT01243359Phase 1
- Sunitinib + Docetaxel as Second-line Treatment in Gastric CancerCompletedNCT01238055Phase 2
- Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell CarcinomaStatus unknownNCT01219751Phase 2
- Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic MelanomaTerminatedNCT01216657Phase 2
- Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)TerminatedNCT01216371Phase 2
- Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine TumorsTerminatedNCT01215578Phase 2
- Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar CarcinomaTerminatedNCT01215565Phase 2
- Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerStatus unknownNCT01210053Phase 2
- Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) DiseaseCompletedNCT01168440Phase 2
- Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)CompletedNCT01122615Phase 1
- Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract CancerStatus unknownNCT01118039Phase 2
- Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma PatientsCompletedNCT01100177Phase 2
- Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)CompletedNCT01089088Phase 2
- Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and SunitinibCompletedNCT01070706Phase 1/2
- Study of Sunitinib in Subjects With High Risk Renal Cell CarcinomaWithdrawnNCT01070186Phase 2
- Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)Status unknownNCT01069770Phase 2
- Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by SurgeryCompletedNCT01061411Phase 1
- Sunitinib in Metastatic Renal CancerCompletedNCT01034878Phase 2
- Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney CancerCompletedNCT01024205Phase 2
- Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRICompletedNCT01020630Phase 2
- Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung CancerStatus unknownNCT01019798Phase 2
- Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant MelanomaCompletedNCT01005472Phase 1
- Stereotactic Radiosurgery With Sunitinib for Brain MetastasesCompletedNCT00981890Phase 1
- Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus SunitinibCompletedNCT00979966Phase 2
- Maintenance Therapy With Sunitinib or Observation in Metastatic Pancreatic CancerCompletedNCT00967603Phase 2
- Sunitinib Malate in Treating Patients With Small Cell Lung CancerTerminatedNCT00953459Phase 2
- Sunitinib Malate in Treating Patients With Kidney CancerCompletedNCT00943839Not applicable
- Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by SurgeryWithdrawnNCT00936832Phase 2
- Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast CancerStatus unknownNCT00931450Phase 1/2
- Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell CarcinomaTerminatedNCT00930345Phase 4
- Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and NeckTerminatedNCT00906360Phase 1
- An Explorative Study on the Pharmacokinetics and Pharmacodynamics of Sunitinib in Healthy VolunteersCompletedNCT00904657Phase 1
- Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma PatientsCompletedNCT00891475Phase 1/2
- Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
- A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary GlandsCompletedNCT00886132Phase 2
- Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid TumorsCompletedNCT00884676Phase 1
- Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent GlioblastomaCompletedNCT00864864Early Phase 1
- To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.CompletedNCT00861419Phase 1
- Activity Study of Sunitinib In Metastatic Pretreated Urothelial CancerStatus unknownNCT00818350Phase 1/2
- Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the BrainCompletedNCT00814021Phase 2
- Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to ChemotherapyCompletedNCT00813423Phase 1
- FOLFIRI and Sunitinib in Metastatic Colorectal CancerCompletedNCT00806663Phase 2
- Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell CancerCompletedNCT00792025Phase 2
- Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical ProstatectomyCompletedNCT00790595Phase 1
- A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell CarcinomaCompletedNCT00788060Phase 1
- Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 YearsCompletedNCT00783653Phase 1/2
- Sunitinib and Radiation in Patients With Resectable Soft-tissue SarcomaStatus unknownNCT00753727Phase 1/2
- An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate CancerCompletedNCT00748358Phase 2
- Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By SurgeryTerminatedNCT00747305Phase 1
- A Phase I Trial of Bortezomib and SunitinibCompletedNCT00720148Phase 1
- Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)Active, not recruitingNCT00715442Phase 2
- Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma TreatmentCompletedNCT00678119Phase 2
- First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic CancerCompletedNCT00673504Phase 2
- Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous NefrectomyCompletedNCT00663559Phase 2
- Clinical Trial of Sutent to Treat Metastatic MelanomaCompletedNCT00631618Phase 2
- Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate CancerCompletedNCT00631527Phase 1
- Sunitinib Before or After Surgery in Treating Patients With Metastatic Kidney CancerStatus unknownNCT00626509Phase 2
- Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung CancerCompletedNCT00620347Phase 2
- A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered TogetherCompletedNCT00618124Phase 1
- Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma PatientsCompletedNCT00617253Phase 2
- A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid TumorsCompletedNCT00615446Phase 1
- Ph I SU011248 + Irinotecan in Treatment of Pts w MGCompletedNCT00611728Phase 1
- Interaction Study of Rapamycin and Sunitinib in Patients With Advanced CancersCompletedNCT00583063Early Phase 1
- Erlotinib and Sunitinib in NSCLCCompletedNCT00581789Phase 1
- SU011248 for Platinum-Refractory Urothelial Cancer Evaluation TrialCompletedNCT00578526Phase 2
- Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell CarcinomaWithdrawnNCT00556205Phase 2
- A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00555256Phase 1
- Sutent Maintenance After Response to TaxotereStatus unknownNCT00550810Phase 2